Biote (BTMD) Total Equity: $-48.0 Mil (As of Mar. 2026)


BTMD Biote Corp BTMD
66 GF Score
Price $1.81
GF Value $3.07
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Biote Total Equity?

Biote BTMD -8.21% 66 Total Equity is $-48.0 Mil as of Mar. 2026. GuruFocus rates BTMD with a GF Score™ of 66/100 and a GF Value™ of $3.07 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Biote's total equity for the quarter that ended in Mar. 2026 was $-48.0 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Biote Total Equity Historical Data

* Premium members only.

The historical data trend for Biote's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biote Total Equity Chart

Biote Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 4.13 -58.27 -36.55 -102.20 -50.40

Biote Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -84.83 -78.84 -65.47 -50.40 -47.96
BTMD
66GF Score
Biote Corp BTMD
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biote Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Biote's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=107.613-158.01
=-50.4

Biote's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=89.032-136.987
=-48.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-48.0 Mil mean?
Biote (BTMD) has a Total Equity of $-48.0 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Biote and its competitors.
Is Biote's Total Equity too high?
Biote's current Total Equity is $-48.0 Mil. Overall, Biote has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biote's Total Equity compare to DCGO and PIII?
Biote's Total Equity of $-48.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Healthcare Providers & Services company?
A good Total Equity depends on the Healthcare Providers & Services industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Biote and its competitors. Biote's current Total Equity is $-48.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biote stock overvalued right now?
Based on GuruFocus' analysis, Biote (BTMD) is currently considered Significantly Undervalued. The stock's GF Value™ is $3.07, compared to a current price of $1.81 — trading 41.2% below its estimated fair value. The current Total Equity is $-48.0 Mil. Biote's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Biote (BTMD), the current Total Equity is $-48.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biote (BTMD) Overvalued in 2026?

Based on GuruFocus' analysis, Biote stock appears to be undervalued. The current stock price of $1.81 is trading 41.2% below its estimated GF Value™ of $3.07. GuruFocus considers Biote to be Significantly Undervalued.

Key valuation signals for BTMD:

  • Total Equity: $-48.0 Mil
  • GF Value™: $3.07 vs. price of $1.81 (41.2% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the BTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biote Business Description

Address 1875 W. Walnut Hill Lane, Suite 100, Irving, TX, USA, 75038
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
66GF Score

Get the complete analysis for BTMD

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.81
Price
$3.07
GF Value